Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Rezurock belumosudil Graft-versus-host disease Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Psoriatic Arthritis, adults Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib atopic dermatitis Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Crohns disease Reimburse with clinical criteria and/or conditions Complete
Rituxan Rituximab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Rituxan Rituximab Acute Lymphoblastic Leukemia Do not reimburse Complete
Rituxan Rituximab Granulomatosis with polyangiitis and microscopic polyangiitis List with clinical criteria and/or conditions Complete